DOI
https://doi.org/10.18849/ve.v5i1.244Abstract
Objective: This field trial aimed to assess the effect of a multivalent clostridial and Pasteurella vaccine (Heptavac P Plus, MSD Animal Health, 2015), administered to lambs at two different time points, on lamb mortality (primary outcome), morbidity and growth rates (secondary outcomes) as compared to unvaccinated lambs.
Background: This veterinary practice-based study was motivated by a knowledge gap identified during flock health planning activities and engagement between veterinarians and commercial sheep producers in a regional knowledge exchange programme in South West England. Common queries to the veterinary practice from sheep producers during summer to autumn 2012 included the value and timing of vaccinations to prevent disease associated with pasteurellosis. Discussions between veterinarians and consultants working in preventive sheep flock health planning stimulated a scientific literature search, which highlighted the lack of published data on field vaccine testing of Pasteurella components under British sheep commercial farming systems, and a lack of strong evidence in order to inform practical questions regarding the optimal timing of vaccinations aimed at preventing lamb mortalities in the pre-, peri- and post-weaning periods.
Evidentiary value: A field vaccine trial was conducted on six commercial sheep flocks in South West England. From April 2013, across the six farms a total of 900 twin-born lambs (Ovis aries) were systematically randomly allocated into 1. unvaccinated, 2. early- (6 to 8-week-old) or 3. late- (18 to 20-week-old) vaccination groups. The study provides evidence to support recommendations for sheep producers regarding risks for clostridial disease in fully unvaccinated sheep flocks, supports the benefits of preventive ewe vaccination, and indicates that pre-weaning vaccination of lambs may be beneficial for reducing peri- and post-weaning losses on some flocks. The study highlights the challenges of identifying the reasons for mortality in grazing lambs, and provides new evidence to support the need for early intervention and treatment of ocular lesions in young lambs, in order to reduce their negative impact on lamb performance.
Methods. During the 6-month trial, lambs were assessed for ocular lesions, orf lesions, clinical respiratory disease, lameness, diarrhoea, and ear tag losses. Monthly liveweights (kg) and mortalities were recorded. Lambs were removed from the study when they reached producer-defined finishing objectives, ≥46 kg liveweight or when they died.
Results: Overall, low levels of mortality and disease outcomes were observed in both control and vaccinated lambs. A mortality rate of 33 deaths per 1000 lambs at-risk, 0.8% lameness (95% CI 0.6–1.1), 1.7% diarrhoea (95% CI 1.4–2.2), 3% ocular disease (including ocular discharge and/or entropion) (95% CI 2.2–3.2), and 2.6% orf lesions (95% CI 2.2–3.1) were recorded over the trial period. A higher proportion of mortalities occurred in unvaccinated or partially vaccinated lambs (n=23; 76.7%), as compared to trial lambs that had received a primary vaccine course (n=7; 13.3%). A small proportion of mortalities (n=3; 10.0%) occurred in lambs whose vaccination status could not be confirmed No clinical signs of respiratory disease were recorded during veterinary or producer assessments of control or vaccinated trial lambs. Mixed-effects models found significant between-farm and time differences in liveweights (p<0.001) but no significant effect of vaccination status on lamb growth rates. A dramatic decrease in lamb growth rates across all farms coincided with the weaning period – this was also the period in the study were the majority of grazing lamb mortalities were identified in flocks that routinely vaccinated their ewes against clostridial disease and pastuerellosis.
Conclusion: A clear trend was found with fewer mortalities occurring in lambs that received a multivalent clostridial and Pastuerella spp. vaccination course compared to unvaccinated lambs. The reasons behind mortalities in grazing lambs were not diagnosed given the low submission of carcases for veterinary necropsy examination that was attributed to carcase scavenging and decomposition. No significant effects of vaccination were found on lamb growth rates or clinical outcomes. However, a secondary finding was the significant negative effect of ocular conditions (including discharge and entropion) on growth rates of lambs aged 6 weeks and over – supporting the need for early recognition and intervention in order to reduce animal welfare and production impacts.
Application: We highlight study findings, field experiences and discuss some of the practical challenges and considerations in design and conduct of field vaccine trials used to inform evidence-based veterinary practice. The study will be of interest to veterinary surgeons, sheep producers, flock health and agricultural consultants, pharmaceutical agencies and advisors, researchers and those engaged in applied studies in animal health and welfare, veterinary epidemiology, preventive health management researchers, and participants and advisors in field vaccine trial design and development.
References
AHPA. Animal Health and Plant Agency Sheep Disease Surveillance Dashboard.
Al Saif, N. & Brazier, J.S. 1996. The distribution of clostridium difficile in the environment of South Wales. Journal of Medical Microbiology. 45: 2, 133–137. DOI: http://dx.doi.org/10.1099/00222615-45-2-133
Brown, K.K., Parizek, R.E. & Stewart, R.C. 1976. Prevention of clostridial disease in cattle and sheep by vaccination with a multivalent bacterin-toxoid. Veterinary Medicine Small Animal Clinics. 71: 12, 1717–1722.
Cassirer, E.F., Rudolph, K.M., Fowler, P., Coggins, V.L., Hunter, D.L. & Miller, M.W. 2001. Evaluation of ewe vaccination as a tool for increasing bighorn lamb survival following pasteurellosis epizootics. Journal of Wildlife Diseases. 37: 1, 49–57. DOI: http://dx.doi.org/10.7589/0090-3558-37.1.49
Chandrasekaran, S., Hizat K., Saad, Z, Johara, M.Y. & Yeap, P.C. 1991. Evaluation of combined Pasteurella vaccines in control of sheep pneumonia. British Veterinary Journal. 147: 5, 437–443. DOI: http://dx.doi.org/10.1016/0007-1935(91)90086-3
Daniel, J.A., Held, J.E., Brake, D.G., Wulf, D.M. & Epperson, W.B. 2006. Evaluation of the prevalence and onset of lung lesions and their impact on growth of lambs. American Journal of Veterinary Research. 67: 5, 890–894. DOI: http://dx.doi.org/10.2460/ajvr.67.5.890
Dean, R., Royle, N., Boulton, C., Turner, S., Mckenzie, B., O’Connor, A., Budsberg, S., Pion, P., Lambert, A., Jarvis, S. & Reynolds, S. 2015. Veterinary All Trials Initiative. Veterinary Record. 177: 5, 131–132. DOI: http://dx.doi.org/10.1136/vr.h4107
Donachie, W. 2007. Pasteurellosis. In Diseases of Sheep, Fourth edition. Ed. Aitken, I.D. Blackwell Publishing, Oxford, United Kingdom, pp 224–231.
Dohoo, I., Martin, W. & Stryhn, H. 2009. Controlled Studies. In: Veterinary Epidemiologic Research, Second Edition. VER Inc, Charlottetown, Prince Edward Island, Canada, pp 213–237.
European Agency for the Evaluation of Medicinal Products (EMEA). 2001. Note for guidance. Field trials with veterinary vaccines.
Gascoigne, G. & Lovatt, F. 2015. Lamb growth rates and optimising production. In Practice. 37, 401–414. DOI: http://dx.doi.org/10.1136/inp.h4537
Gilmour, N.J., Martin, W.B., Sharp, J.M., Thompson, D.A. & Wells, P.W. 1979. The development of vaccines against pneumonic pasteurellosis in sheep. Veterinary Record. 104: 15, 266–269. DOI: http://dx.doi.org/10.1136/vr.104.1.15
Green, D.S., Green, M.J., Hillyer, M.H. & Morgan, K.L. 1987. Injection site reactions and antibody responses in sheep and goats after the use of multivalent clostridial vaccines. Veterinary Record. 120, 435–439. DOI: http://dx.doi.org/10.1136/vr.120.18.435
Goodwin-Ray, K.A., Stevenson, M.A. & Huer, C. 2008. Effect of vaccinating lambs against pneumonic pasteurellosis under New Zealand field conditions on their weight gain and pneumonic lung lesions at slaughter. Veterinary Record. 162, 9–11. DOI: http://dx.doi.org/10.1136/vr.162.1.9
Jones, G.E., Donachie, W., Sutherland, A.D., Knox, D.P. & Gilmour, J.S. 1989. Protection of lambs against experimental pasteurellosis by transfer of immune serum. Veterinary Microbiology. 20: 1, 59–71. DOI: http://dx.doi.org/10.1016/0378-1135(89)90007-2
Knight-Jones, T.J.D., Edmond, K., Gubbins, S. & Paton, D.J. 2014. Veterinary and human vaccine evaluation methods. Proceedings of the Royal Society. 281. DOI: http://dx.doi.org/10.1098/rspb.2013.2839
Lewis, C.J. 2007. Clostridial diseases. In: Diseases of Sheep, Forth edition. Ed Aitken, I.D. Blackwell Publishing, Oxford, United Kingdom, pp 156–167.
Lovatt, F.M., Barker, W.J.W., Brown, D. & Spooner, R.K. 2012. Case-control study of orf in preweaned lambs and an assessment of the financial impact of the disease. Veterinary Record. 170, 673–677. DOI: http://dx.doi.org/10.1136/vr.100646
Malone, F.E., McCullough, S.J., McLoughlin, M.F., Ball, H.J., O'Hagan, J. & Neill, S.D. 1988. Infectious agents in respiratory disease of housed, fattening lambs in Northern Ireland. Veterinary Record. 122, 203–207. DOI: http://dx.doi.org/10.1136/vr.122.9.203
MSD Animal Health. 2015. Datasheet for Heptavac-P Plus.
Phythian, C.J., Cripps, P.J., Michalopoulou, E., Jones, P.H., Grove-White, D., Clarkson, M.J., Winter, A.C., Stubbings, L.A. & Duncan, J.S. 2012. Reliability of indicators of sheep welfare assessed by a group observation method. The Veterinary Journal. 193: 1, 257–263. DOI: https://doi.org/10.1016/j.tvjl.2011.12.006
Phythian, C.J., Toft, N., Cripps, P.J., Michalopoulou, E., Winter, A.C., Jones, P.H., Grove-White, D. & Duncan, J.S. 2013. Inter-observer agreement, diagnostic sensitivity and specificity of animal-based indicators of young lamb welfare. Animal. 7: 7, 1182–1190. DOI: http://dx.doi.org/10.1017/S1751731113000487
RUMA. 2006. Responsible use of medicines in agriculture alliance guidelines. Responsible use of vaccines and vaccination in sheep production.
Sanderson, M.W. 2006. Designing and running clinical trials on farms. Veterinary Clinics of North America: Food Animal Practice. 22: 1, 103–123. DOI: http://dx.doi.org/10.1016/j.cvfa.2005.11.004
Sargeant, J.M., O'Connor, A.M., Gardner, I.A., Dickson, J.S., Torrence, M.E., Dohoo, I.R., Lefebvre, S.L., Morley, P.S., Ramirez, A. & Snedeker, K. 2010. The REFLECT statement: reporting guidelines for randomized controlled trials in livestock and food safety: explanation and elaboration. Journal of Food Protection. 73: 3, 579–603. DOI: http://dx.doi.org/10.4315/0362-028X-73.3.579
Scott, P.R. & Sargison, N.D. 2010. Ultrasonography as an adjunct to clinical examination in sheep. Small Ruminant Research. 92: 1-3, 108–109. DOI: http://dx.doi.org/10.1016/j.smallrumres.2010.04.011
Uzal, F.A., Kelly, W.R., Morris, W.E., Bermudez, J. & Baisón, M. 2004. The pathology of peracute experimental Clostridium perfringens type D enterotoxemia in sheep. Journal of Veterinary Diagnostic Investigation. 16: 5, 403–411. DOI: http://dx.doi.org/10.1177/104063870401600506
Uzal, F.A. 2004. Diagnosis of Clostridium perfringens intestinal infections in sheep and goats. Anaerobe. 10: 2, 135–143. DOI: http://dx.doi.org/10.1016/j.anaerobe.2003.08.005
Wells, P.W., Evans, H.B., Burrells, C., Sharp, J.M., Gilmour, N.J., Thompson, D.A. & Rushton, B. 1979. Inability of passively acquired antibody to protect lambs against experimental pasteurellosis. Infection and Immunity. 26: 1, 25–29. DOI: http://dx.doi.org/10.1128/IAI.26.1.25-29.1979
Wells, P.W., Robinson, J.T., Gilmour, N.J., Donachie, W. & Sharp, J.M. 1984. Development of a combined clostridial and Pastuerella haemolytica vaccine for sheep. Veterinary Record. 114, 266–269. DOI: http://dx.doi.org/10.1136/vr.114.11.266
Zheng, T., Gupta, S.K., McCarthy, A.R., Moffat, J. & Buddle, B.M. 2015. Cross-protection study of a Mannheimia haemolytica serotype 1 vaccine against acute pasteurellosis in lambs induced by a serotype 2 strain. Veterinary Microbiology. 177: 3-4, 386–393. DOI: http://dx.doi.org/10.1016/j.vetmic.2015.02.019
License
Veterinary Evidence uses the Creative Commons copyright Creative Commons Attribution 4.0 International License. That means users are free to copy and redistribute the material in any medium or format. Remix, transform, and build upon the material for any purpose, even commercially - with the appropriate citation.
